Marshfield Clinic Research Foundation, 1000 N. Oak Avenue, Marshfield, WI, 54449, USA.
Prevention Genetics, Marshfield, WI, USA.
Osteoporos Int. 2017 Aug;28(8):2343-2348. doi: 10.1007/s00198-017-4035-y. Epub 2017 Apr 12.
A majority of adults with persistently low serum alkaline phosphatase values carry a pathogenic or likely pathogenic variant in the ALPL gene and also have elevated alkaline phosphatase substrate values in serum and urine. These adults may fall within the spectrum of the adult form of hypophosphatasia.
The primary objective of this study was to determine what proportion of adults with persistently low serum alkaline phosphatase values (hypophosphatasemia) harbor mutations in the ALPL gene or have elevated alkaline phosphatase (ALP) substrates. Some adults with persistent hypophosphatasemia share clinical and radiographic features with the adult form of hypophosphatasia (HPP). In HPP, ALPL mutations result in persistent hypophosphatasemia and ALP substrate accumulation in plasma (pyridoxal-5-phosphate (PLP)) and urine (phosphoethanolamine (PEA)).
Biochemical analyses, including serum ALP activity, bone-specific ALP, plasma PLP, and urine PEA, were performed in adults with persistent hypophosphatasemia. Mutational analyses were performed using PCR and Sanger sequencing methods. Gene variants were classified as pathogenic (P), likely pathogenic (LP), variants of uncertain significance (VUS), likely benign (LB), and benign (B). P and LP variants were further grouped as "Positive ALPL variants" and LB and B grouped as "Negative ALPL variants."
Fifty subjects completed all mutational and biochemical analyses. Sixteen percent carried only Negative ALPL variants. Of the remaining 42 subjects, 67% were heterozygous for a P variant, 19% for an LP variant, and 14% for a VUS. Biochemical results were highly inter-correlated and consistent with the expected inverse relationship between ALP and its substrates. Subjects harboring Positive ALPL variants showed lower ALP and BSAP and higher PLP and PEA values compared with subjects harboring only Negative ALPL variants. Approximately half of all subjects harboring Positive ALPL variants or ALPL VUS showed elevations in plasma PLP, and three quarters showed elevations in urine PEA.
Adults with persistent hypophosphatasemia frequently harbor ALPL mutations and have elevated ALP substrates. These adults may fall within the spectrum of the adult form of hypophosphatasia. Clinicians should take note of persistent hypophosphatasemia in their patients and be cautious in prescribing bisphosphonates when present.
大多数持续低血清碱性磷酸酶值的成年人携带 ALPL 基因的致病性或可能致病性变异,并且血清和尿液中的碱性磷酸酶底物值也升高。这些成年人可能属于成人型低磷酸酶血症的范畴。
本研究的主要目的是确定持续低血清碱性磷酸酶值(低磷酸血症)的成年人中有多少人携带 ALPL 基因突变或有升高的碱性磷酸酶(ALP)底物。一些持续低磷酸血症的成年人与成人型低磷酸酶血症(HPP)有共同的临床和影像学特征。在 HPP 中,ALPL 突变导致持续低磷酸血症和 ALP 底物在血浆(吡哆醛-5-磷酸(PLP))和尿液(磷酸乙醇胺(PEA))中积聚。
对持续低磷酸血症的成年人进行生化分析,包括血清 ALP 活性、骨特异性 ALP、血浆 PLP 和尿液 PEA。使用 PCR 和 Sanger 测序方法进行基因突变分析。基因变异被分类为致病性(P)、可能致病性(LP)、意义不明的变异(VUS)、可能良性(LB)和良性(B)。P 和 LP 变体进一步分为“阳性 ALPL 变体”,LB 和 B 分为“阴性 ALPL 变体”。
50 名受试者完成了所有的突变和生化分析。16%的人只携带阴性 ALPL 变体。在其余 42 名受试者中,67%为 P 变体杂合子,19%为 LP 变体杂合子,14%为 VUS。生化结果高度相关,与 ALP 与其底物之间的预期反比关系一致。携带阳性 ALPL 变体的受试者的 ALP 和 BSAP 较低,PLP 和 PEA 值较高,与仅携带阴性 ALPL 变体的受试者相比。携带阳性 ALPL 变体或 ALPL VUS 的受试者中有一半以上的人血浆 PLP 升高,四分之三的人尿液 PEA 升高。
持续低磷酸血症的成年人常携带 ALPL 基因突变,且 ALP 底物升高。这些成年人可能属于成人型低磷酸酶血症的范畴。临床医生应注意患者持续低磷酸血症,并在存在时谨慎使用双膦酸盐。